Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04169321 · ClinicalTrials.gov registry record · Phase 1
Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors
A Phase 1 study of Lymphoma and Solid Tumor, Unspecified, Adult, sponsored by Cytosite Biopharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 3
- Study locations
NCT04169321 is a Phase 1 study of Lymphoma and Solid Tumor, Unspecified, Adult that has completed, run by Cytosite Biopharma. The registered enrollment target is 13 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT04169321, a Phase 1 study of Lymphoma and Solid Tumor, Unspecified, Adult, has completed, sponsored by Cytosite Biopharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 3
- Study locations
Study Summary
First in Human Safety of \[68Ga\]-NOTA-hGZP PET Imaging in subjects with cancer undergoing treatment with a checkpoint inhibitor either as a monotherapy of in combination I-O therapy
Conditions Studied
Interventions
- DRUG Single Arm
Study Locations (3)
Alabama
- University of Alabama at Birmingham - Birmingham
Massachusetts
- Massachusetts General Hospital - Boston
Guishan
- Chang-Gung Memorial Hospital - Taoyuan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2020-06-16 |
| Est. Completion | 2025-06-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04169321
The ClinicalTrials.gov registry entry for NCT04169321 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (97% lower). The listed sponsor is Cytosite Biopharma, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Single Arm is the first listed.
NCT04169321 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Alabama, Massachusetts, Guishan.
Frequently Asked Questions
What is clinical trial NCT04169321 about?
NCT04169321 is a clinical study titled "Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors". First in Human Safety of \[68Ga\]-NOTA-hGZP PET Imaging in subjects with cancer undergoing treatment with a checkpoint inhibitor either as a monotherapy of in combination I-O therapy
What is the current status of trial NCT04169321?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2020-06-16. Estimated completion is 2025-06-09.
What conditions does trial NCT04169321 study?
This clinical trial studies the following conditions: Lymphoma, Solid Tumor, Unspecified, Adult.
What interventions are being tested in trial NCT04169321?
The interventions under investigation include: Single Arm (DRUG).
Who is sponsoring clinical trial NCT04169321?
This trial is sponsored by Cytosite Biopharma, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04169321 being conducted?
This trial has 3 study locations across Alabama, Massachusetts, Guishan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.